3Fujihara A, Norlmatsu Y, Kobayashi TK, et al. Direct intrauterine sampling with Uterobrush: cell preparation by the "flicked" method[J]. Diagn Cytopathol, 2006, 34(7): 486-490.
4Papaefthimiou M, Symiakakl H, Mentzelopoulou P, et al. Study on .the morphology and reproducibility of the diagnosis of endometrial lesions utilizing liquid-based cytology[J]. Cancer Cytopathology, 2005, 105(2): 56-64.
5Mutch DG, Powell MA, Allsworth JE, et al. How accurate is Pipelle sampling: a study by Huang et alia. Am J Obstet Gynecol, 2007, 196(3): 280-281.
6Swerdlow AJ, Jones ME, British Tamoxifen Second Cancer Study Group. Endometrial cancer risk remained elevated years after stopping tamoxifen treatment for breast cancer[J]. Gynecol Oncol, 2005, 10(7): 211-212.
7Jennifer A, Kara L, Babette, et al. Long-term use of postmenopausal estrogen and progestin hormone therapies and the risk of endometrial cancer[]]. American Journal of Obsterics and Gynecol, 2007, 197(2):139. e1-e7.
8Norimatsu Y, Miyamoto T, Kobayashi TK, et al. Utility of thin-layer preparations in endometrial cytology: Immunocytochemical expression of PTEN, beta-catenin and p53 for benign endometrial lesions[J]. Diagn Gytopathol, 2008, 36(4): 216-223.
9Norimatsu Y, Kouda H, Kobayashi TK, et al. Utility of thin-layer preparation in the endometrial cytology: Evaluation of benign endometrial lesions[J]. Ann Diagn Pathol, 2008, 12(2):103-111.
10Nishimura Y, WatanabeJ, Jobo T, et al, Cytologic scoring of endometrioid adenocarcinoma of the endometrium[J]. Cancer, 2005, 105(1): 8-12.
